Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study.
Xiantong ZouYibin LuQi Fu LiLiujun FuYong LuoTao LeiLing LiShandong YeBimin ShiXiyan LiThomas MeinickePublished in: Diabetes, obesity & metabolism (2023)
In Chinese patients with T2D, empagliflozin combined with insulin ± OADs improved glycaemic control and was well tolerated, without an increased risk of hypoglycaemia.